GlassScriptPhysician profile
Dheeraj Dhotre
NPI 1508046368
$9,069.75
in general payments reported to CMS, 2019-2025
41 companies · $813 in 2025
The $813 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $458 · 2021: $960 · 2022: $4,226 · 2023: $723 · 2024: $536 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,885.50 | 2022-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $697.48 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $545.45 | 2019-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $518.80 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $513.81 | 2019-2023 | Opsumit, Uptravi |
| Ethicon INC. | $466.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.78 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $241.11 | 2019-2025 | Dupixent |
| United Therapeutics Corporation | $165.35 | 2019-2025 | Orenitram, Remodulin, Tyvaso |
| Genzyme Corporation | $151.52 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $146.34 | 2020-2023 | |
| Inari Medical, INC. | $132.15 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Philips North America LLC | $108.58 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Amgen INC. | $101.30 | 2021-2025 | Tezspire, Tavneos |
| Genentech USA, INC. | $101.06 | 2019-2025 | Tecentriq |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $92.74 | 2019-2022 | |
| Inspire Medical Systems, INC. | $83.81 | 2024 | Inspire |
| Sunovion Pharmaceuticals INC. | $73.35 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $72.07 | 2019-2025 | Winrevair |
| Takeda Pharmaceuticals U.S.A., INC. | $57.59 | 2021-2025 | Hyqvia |
| Baxter Healthcare | $50.34 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| E.R. Squibb & Sons, L.L.C. | $47.79 | 2019-2021 | |
| Mylan Specialty L.P. | $42.32 | 2020-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $40.81 | 2020-2025 | |
| Insmed, INC. | $37.97 | 2019-2024 | Arikayce |
| Electromed, INC. | $27.77 | 2025 | Smartvest |
| Viatris Specialty LLC | $24.38 | 2025 | Yupelri |
| Abbvie INC. | $24.26 | 2022 | |
| Ucb, INC. | $23.51 | 2019 | |
| Olympus America INC. | $23.07 | 2020 | |
| Alexion Pharmaceuticals, INC. | $22.95 | 2023 | Ultomiris |
| Verona Pharma, INC. | $21.46 | 2025 | Ohtuvayre |
| Allergan, INC. | $21.45 | 2019 | |
| Bard Peripheral Vascular, INC. | $20.65 | 2023 | |
| Pfizer INC. | $20.63 | 2021 | |
| Mallinckrodt Enterprises LLC | $19.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.08 | 2019 | |
| Shire North American Group INC | $17.31 | 2019 | |
| Zoll Respicardia, INC. | $15.62 | 2023 | Remede System |
| Circassia INC. | $13.20 | 2020 | |
| Portola Pharmaceuticals, LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dheeraj Dhotre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.